Who
Paul J. Hastings
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Nkarta; Director, enGene Therapeutics; Director, Pacira BioSciences; Director, Protara Therapeutics; Chairman & CEO, OncoMed Pharmaceuticals; Director, Relypsa; Director, Viacell.
In numbers
- Trades disclosed
- 169
- Buys
- 1
- Sells
- 43
- Bought
- $25K
- Sold
- $5.2M
- Companies
- 7
- Companies where not an officer
- 5
- First trade
- 19 May 2006
- Last trade
- 18 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 22 Jun 2026 | NKTX NkartaBiotechnology | SEC FORM 4 Sold | $4,8131,776 at $2.71 | filing |
| 18 Jun 2026filed 22 Jun 2026 | NKTX NkartaBiotechnology | SEC FORM 4 Sold | $4,8131,776 at $2.71 | filing |
| 16 Jun 2026filed 17 Jun 2026 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 16 Jun 2026filed 17 Jun 2026 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 15 Jan 2026filed 20 Jan 2026 | NKTX NkartaBiotechnology | SEC FORM 4 Sold | $54K26,046 at $2.07 | filing |
| 15 Jan 2026filed 20 Jan 2026 | NKTX NkartaBiotechnology | SEC FORM 4 Sold | $54K26,046 at $2.07 | filing |
| 6 Jan 2026filed 8 Jan 2026 | NKTX NkartaBiotechnology | SEC FORM 4 Code A | —94,000 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | NKTX Nkartaoption or derivative · Biotechnology | SEC FORM 4 Code A | —562,000 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | NKTX Nkartaoption or derivative · Biotechnology | SEC FORM 4 Code A | —562,000 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | NKTX NkartaBiotechnology | SEC FORM 4 Code A | —94,000 at $0.00 | filing |
| 18 Jun 2025filed 20 Jun 2025 | NKTX NkartaBiotechnology | SEC FORM 4 Sold | $3,2041,790 at $1.79 | filing |
| 16 Jun 2025filed 16 Jun 2025 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | NKTX Nkartaoption or derivative · Biotechnology | SEC FORM 4 Code A | —377,000 at $0.00 | filing |
| 15 Jan 2025filed 17 Jan 2025 | NKTX NkartaBiotechnology | SEC FORM 4 Sold | $38K17,378 at $2.20 | filing |
| 3 Jan 2025filed 7 Jan 2025 | NKTX Nkartaoption or derivative · Biotechnology | SEC FORM 4 Code A | —565,500 at $0.00 | filing |
| 3 Jan 2025filed 7 Jan 2025 | NKTX NkartaBiotechnology | SEC FORM 4 Code A | —94,500 at $0.00 | filing |
| 18 Jun 2024filed 20 Jun 2024 | NKTX NkartaBiotechnology | SEC FORM 4 Sold | $9,9121,770 at $5.60 | filing |
| 15 Jun 2024filed 18 Jun 2024 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 13 Jun 2024filed 13 Jun 2024 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $25K880 at $28.38 | filing |
| 12 Jun 2024filed 13 Jun 2024 | PCRX Pacira BioSciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —12,179 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.